免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Lifileucel：首个获批用于实体瘤的细胞疗法
英文原题：Lifileucel: the first cellular therapy approved for solid tumours.
查看英文原题
Lifileucel: the first cellular therapy approved for solid tumours.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
美国食品药品监督管理局（FDA）批准lifileucel用于晚期黑色素瘤，标志着首个细胞疗法进入实体瘤临床。在此，我们总结这一里程碑式的批准，探讨相关的监管路径，并评估确保这一先进“活体”疗法有效实施所仍面临的挑战。
展开英文摘要原文
The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.
论文信息
- 作者
- Julve M、Lythgoe MP、Larkin J、Furness AJS
- 单位
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Maximilian.julve@nhs.net.United Kingdom
- 文献类型
- 综述
- 期刊
- Trends in cancer2024 Jun
- 原文标识
- PubMed 38724322 · DOI 10.1016/j.trecan.2024.04.003